仙台病毒抗肿瘤的研究进展

doi:10.3969/j.issn.1674-5817.2014.06.019

实验动物与比较医学 ›› 2014, Vol. 34 ›› Issue (6): 515-518.DOI: 10.3969/j.issn.1674-5817.2014.06.019

仙台病毒抗肿瘤的研究进展

张泉, 朱慧霞, 李翎瑜, 谭海明, 薛整风

扬州大学兽医学院比较医学中心,扬州 225009

收稿日期:2014-06-12 出版日期:2014-12-25 发布日期:2014-12-25
作者简介:张泉(1979-), 男, 博士, 副教授, 研究方向:实验动物医学。 E-mail:zquan@yzu.edu.cn.
基金资助:
国家自然科学基金(31302042), 江苏省自然科学基金(BK20130045)

Research Progress on Sendai Virus against Tumors

ZHANG Quan, ZHU Hui-xia, LI Ling-yu, TAN Hai-ming, XUE Zheng-feng

Comparative Medicime Center, College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China

Received:2014-06-12 Online:2014-12-25 Published:2014-12-25

摘要/Abstract

摘要： 仙台病毒是实验大、小鼠的常见病原之一。大、小鼠感染仙台病毒后,可通过诱生I型干扰素、调节免疫应答和致肿瘤细胞凋亡等干预肿瘤生长,该病毒已逐渐被开发为一种新型、高效的抗肿瘤制剂。本文综述了仙台病毒抗肿瘤、对科学研究的干扰作用等方面进展。

关键词: 仙台病毒(SeV), 肿瘤, 干扰素, 免疫调节, 凋亡

Abstract: Sendai virus is one of the common pathogens in laboratory rats and mice. Transplanted tumors may be inhibited by type I interferon induction, immune response regulation and directly apoptosis in cancer cells after Sendai virus infection in hosts. Nowadays, Sendai virus has already been gradually developed as an effective and new anti-cancer reagent. In this review, the mechanisms of Sendai virus infection against cancer growth and interference on experiment were described.

Key words: Sendai virus(SeV), Cancer, Interferon, Immune regulation, Apoptosis

中图分类号:

R-332
Q95-33

张泉, 朱慧霞, 李翎瑜, 谭海明, 薛整风. 仙台病毒抗肿瘤的研究进展[J]. 实验动物与比较医学, 2014, 34(6): 515-518.

ZHANG Quan, ZHU Hui-xia, LI Ling-yu, TAN Hai-ming, XUE Zheng-feng. Research Progress on Sendai Virus against Tumors[J]. Laboratory Animal and Comparative Medicine, 2014, 34(6): 515-518.

参考文献

[1] 袁立军, 李晓眠, 李梅. 仙台病毒基因结构与功能的研究进展[J]. 中国病原生物学杂志, 2006, 1(6):462-464.
[2] 隋丽华, 范薇, 杨敬, 等. 实验动物微生物、寄生虫抽样调查及分析[J]. 实验动物与比较医学, 2008, 28(4):259-262.
[3] 魏晓峰, 胡建华, 高诚. 仙台病毒核蛋白的原核表达及鉴定[J]. 中国动物传染病学报, 2010, 18(4):32-36.
[4] Kawaguchi Y, Miyamoto Y, Inoue T, et al.Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle[J]. Int J Cancer, 2009, 124(10):2478-2487.
[5] Zhang Q, Yuan WF, Zhai GQ, et al.Inactivated Sendai Virus Suppresses Murine Melanoma Growth by Inducing Host Immune Responses and Down-regulating β-catenin Expression[J]. Biomed Environ Sci, 2012, 25(5):509-516.
[6] Kimura T, Nakamura H, Koyama S, et al.In vivo gene transfer into the mouse uterus: a powerful tool for investigating implantation physiology[J]. J Reprod Immunol, 2005, 67(1-2):13-20.
[7] Matsuda M, Yamamoto T, Matsumura A, et al.Highly efficient eradication of intracranial glioblastoma using Eg5 siRNA combined with HVJ envelope[J]. Gene Ther, 2009, 16(12):1465-1476.
[8] Kondo Y, Fushikida K, Fujieda T, et al.Efficient delivery of antibody into living cells using a novel HVJ envelope vector system[J]. J Immunol Methods, 2008, 332(1-2):10-17.
[9] Kaneda Y, Nakajima T, Nishikawa T, et al.Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system[J]. Mol Ther, 2002, 6(2):219-226.
[10] Kaneda Y.Virosome: a novel vector to enable multi-modal strategies for cancer therapy[J]. Adv Drug Deliv Rev, 2012,64(8):730-738.
[11] Fujihara A, Kurooka M, Miki T, et al.Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation[J]. Cancer Immunol Immunother,2008, 57(1):73-84.
[12] Zhang Q, Wang Z, Yuan Y, et al.Immunoadjuvant effects of hemagglutinating virus of Japan envelope (HVJ-E) on the inactivated H9 subtype avian influenza virus vaccine[J]. Vet Immunol Immunopathol, 2011, 141(1-2):116-123.
[13] Yoneyama Y, Ueda Y, Akutsu Y, et al.Development of immunostimulatory virotherapy using non-transmissible Sendai virus-activated dendritic cells[J]. Biochem Biophys Res Commun, 2007, 355(1):129-135.
[14] Kurooka M, Kaneda Y.Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells[J]. Cancer Res, 2007, 67(1):227-236.
[15] Suzuki H, Kurooka M, Hiroaki Y, et al.Sendai virus F glycoprotein induces IL-6 production in dendritic cells in a fusion-independent manner[J]. FEBS Lett, 2008, 582(9):1325-1329.
[16] Shibata S, Okano S, Yonemitsu Y, et al.Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-beta gene[J]. J Immunol, 2006, 177(6):3564-3576.
[17] Tanaka M, Shimbo T, Kikuchi Y, et al.Sterile alpha motif containing domain 9 is involved in death signaling of malignant glioma treated with inactivated Sendai virus particle (HVJ-E) or type I interferon[J]. Int J Cancer, 2010, 126(8):1982-1991.
[18] Kaneda Y, Kiyohara E, Itai T, et al.Gene Therapy of Melanoma Using Inactivated Sendai Virus Envelope Vector (HVJ-E) with Intrinsic Anti-Tumor Activities: InTech, 2011.
[19] Zhang Q, Xu X, Yuan Y, et al.IPS-1 plays a dual function to directly induce apoptosis in murine melanoma cells by inactivated Sendai virus[J]. Int J Cancer, 2014, 134(1):224-234.
[20] Gao H, Xu XS, Chen ZD, et al.Inactivated Sendai virus induces apoptosis in murine melanoma cells by IGF-1R down-regulation[J].Biomed Environ Sci, 2012, 26(12):998-1002.
[21] Samani AA, Yakar S, LeRoith D, et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights[J]. Endocr Rev, 2007, 28(1):20-47.
[22] Karasic TB, Hei TK, Ivanov VN.Disruption of IGF-1R signaling increases TRAIL-induced apoptosis: a new potential therapy for the treatment of melanoma[J]. Exp Cell Res, 2010, 316(12):1994-2007.
[23] Kawano H, Komaba S, Kanamori T, et al.A new therapy for highly effective tumor eradication using HVJ-E combined with chemotherapy[J]. BMC Med, 2007, 5:28.
[24] Takehara Y, Satoh T, Nishizawa A, et al.Anti-tumor effects of inactivated Sendai virus particles with an IL-2 gene on angiosarcoma[J]. Clin Immunol, 2013, 149(1):1-10.

仙台病毒抗肿瘤的研究进展

Research Progress on Sendai Virus against Tumors

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	翟珊珊, 梁亮, 曹颖颖, 李竹欣, 王青, 陶俊宇, 运晨霞, 冷静, 唐海波. 一例树鼩毛发上皮瘤的诊断及细胞生物学特性观察[J]. 实验动物与比较医学, 2023, 43(4): 440-445.
[2]	刘甦苏, 吴勇, 曹愿, 赵皓阳, 翟世杰, 孙晓炜, 李琳丽, 范昌发. hKDR^+/+ 人源化及Rag1^-/-基因缺陷新型双靶点遗传修饰荷瘤小鼠模型的建立[J]. 实验动物与比较医学, 2023, 43(2): 103-111.
[3]	毛璐婧, 张娜娜, 刘昊, 史爱华, 朱子语, 吕毅. 适用于微创消融治疗研究的小鼠胰腺癌原位模型建立方法及比较[J]. 实验动物与比较医学, 2022, 42(2): 127-134.
[4]	宋伟杰, 周岩, 牛瑞芳. 人源肿瘤异种移植动物模型在癌症精准医学研究中的应用[J]. 实验动物与比较医学, 2021, 41(6): 493-500.
[5]	张波扬, 陈焕鹏, 余文兰, 刘忠华, 黄朝峰. MC38结肠癌小鼠肿瘤浸润免疫细胞的动态变化[J]. 实验动物与比较医学, 2021, 41(5): 409-417.
[6]	肖攀, 牛廷献, 罗晓红, 王红义, 郭晓宇, 陆璐, 冯小明. 高原多脏器功能障碍综合征蕨麻猪模型C反应蛋白及炎性因子的变化[J]. 实验动物与比较医学, 2021, 41(3): 238-243.
[7]	李洪波, 黄锐, 代将, 钟振东. 竹节香附素A对肝缺血再灌注大鼠的保护作用机制[J]. 实验动物与比较医学, 2021, 41(1): 55-60.
[8]	张晓节, 蒋磊. 基于网络药理学探究白藜芦醇抗大鼠心肌缺血再灌注损伤的分子机制[J]. 实验动物与比较医学, 2020, 40(6): 496-505.
[9]	罗宝花, 张永斌, 刘晓秋, 师长宏. 肿瘤类器官模型的建立及应用[J]. 实验动物与比较医学, 2020, 40(6): 540-546.
[10]	何大伟, 何敖林, 周明慧, 于亚平, 张明华. 草氨酸钠对胆管癌细胞自噬与凋亡的影响[J]. 实验动物与比较医学, 2020, 40(5): 403-.
[11]	周晓丽, 张倩, 高峥, 钱智勇. 老年SD大鼠自发性肿瘤的病理学观察[J]. 实验动物与比较医学, 2020, 40(5): 420-.
[12]	康瑜, 杨小芳. 纳米脂质体槲皮素对脑缺血再灌注损伤的神经保护作用及机制[J]. 实验动物与比较医学, 2020, 40(2): 116-122.
[13]	王爱红, 王明全, 杜娟. O-N-乙酰葡萄糖胺糖基化水平正调控促血管生成素-2表达从而促进小鼠肝癌中肿瘤新生血管形成[J]. 实验动物与比较医学, 2020, 40(1): 39-46.
[14]	陈超, 丛薇, 杨文静, 崔淑芳. 裸鼹鼠抗化学诱癌因素特性的研究[J]. 实验动物与比较医学, 2019, 39(6): 484-488.
[15]	胡斌权, 储海盟, 师长宏. 人源性异种移植模型在胰腺癌个体化治疗研究中的应用[J]. 实验动物与比较医学, 2019, 39(6): 499-504.